XML 38 R16.htm IDEA: XBRL DOCUMENT
v3.4.0.3

Commitments and Contingencies | 6 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2015 | Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract] |  |
Commitments and Contingencies Disclosure [Text Block] | ## Note 7 — Commitments and Contingencies Commitments and contingencies are described below and summarized by the following table for the designated fiscal years ending June 30, as of December 31, 2015:
|  | Total |  | Remaining 2016 |  | 2017 |  | 2018 |  | 2019 |  | 2020 |  | Thereafter
Management fee |  | $ | 1,620,000 |  |  | $ | 180,000 |  |  | $ | 360,000 |  |  | $ | 360,000 |  |  | $ | 360,000 |  |  | $ | 360,000 |  |  | $ | — |
Primsol business |  |  | 1,250,000 |  |  |  | 1,000,000 |  |  |  | 250,000 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Manufacturing agreement |  |  | 1,000,000 |  |  |  | 1,000,000 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Office Lease |  |  | 385,000 |  |  |  | 68,000 |  |  |  | 142,000 |  |  |  | 145,000 |  |  |  | 30,000 |  |  |  | — |  |  |  | — |
Sponsored research agreement with related party |  |  | 315,000 |  |  |  | 35,000 |  |  |  | 70,000 |  |  |  | 70,000 |  |  |  | 70,000 |  |  |  | 70,000 |  |  |  | — |
|  | $ | 4,570,000 |  |  | $ | 2,283,000 |  |  | $ | 822,000 |  |  | $ | 575,000 |  |  | $ | 460,000 |  |  | $ | 430,000 |  |  | $ | — |
### Management Fee In July 2015, Aytu entered into an agreement with Ampio whereby Aytu agreed to pay Ampio $30,000 per month for shared overhead which includes costs related to the shared facility, corporate staff, and other miscellaneous overhead expenses. This agreement will be in effect until it is terminated in writing by both parties. ### Primsol Business In October 2015, Aytu entered into an agreement with FSC Laboratories, Inc. for the purchase of Primsol (see Note 1). ### Manufacturing Agreement In October 2015, Aytu entered into a Master Services Agreement with Biovest International, Inc. (“Biovest”). The agreement provides that Aytu may engage Biovest from time to time to provide services in accordance with mutually agreed upon project addendums and purchase orders. Aytu expects to use the agreement from time to time for manufacturing services, including without limitation, the manufacturing, processing, quality control testing, release or storage of its products for the ProstaScint product. Aytu is obligated to pay Biovest $1.0 million for time and materials as they develop a plan to reproduce the manufacturing process. ### Office Lease In June 2015, Aytu entered into a 37 month operating lease for a space in Raleigh, North Carolina. This lease has initial base rent of $2,900 a month, with total base rent over the term of the lease of approximately $112,000. In September 2015, the Company entered into a 37 month operating lease in Englewood, Colorado. This lease has an initial base rent of $8,500 a month with a total base rent over the term of the lease of approximately $318,000. The Company recognizes rental expense of the facilities on a straight-line basis over the term of the lease. Differences between the straight-line net expenses on rent payments are classified as liabilities between current deferred rent and long-term deferred rent. Rent expense for the respective periods is as follows:
|  | Three Months Ended December 31, |  | Six Months Ended December 31,
|  | 2015 |  | 2014 |  | 2015 |  | 2014
Rent expense |  | $ | 34,000 |  |  | $ | 22,000 |  |  | $ | 51,000 |  |  | $ | 40,000 |
### Sponsored Research Agreement with Related Party Aytu entered into a Sponsored Research Agreement with Trauma Research LLC (“TRLLC”), a related party, in June 2013. Under the terms of the Sponsored Research Agreement, TRLLC agreed to work collaboratively in advancing the RedoxSYS System diagnostic platform through research and development efforts. The Sponsored Research Agreement may be terminated without cause by either party on 30 days’ notice.
| ## Note 5 — Commitments and Contingencies Commitments and contingencies are described below and summarized by the following table as of June 30, 2015:
|  | Total |  | 2016 |  | 2017 |  | 2018 |  | 2019 |  | 2020 |  | Thereafter
Management fee |  | $ | 1,800,000 |  |  | $ | 360,000 |  |  | $ | 360,000 |  |  | $ | 360,000 |  |  | $ | 360,000 |  |  | $ | 360,000 |  |  | $ | — |
ProstaScint Inventory Transfer |  |  | 500,000 |  |  |  | 500,000 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Sponsored research agreement with related party |  |  | 350,000 |  |  |  | 70,000 |  |  |  | 70,000 |  |  |  | 70,000 |  |  |  | 70,000 |  |  |  | 70,000 |  |  |  | — |
Clinical research and trial obligations |  |  | 329,000 |  |  |  | 329,000 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Manufacturing |  |  | 133,000 |  |  |  | 133,000 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Office Lease |  |  | 110,000 |  |  |  | 35,000 |  |  |  | 36,000 |  |  |  | 36,000 |  |  |  | 3,000 |  |  |  | — |  |  |  | — |
|  | $ | 3,222,000 |  |  | $ | 1,427,000 |  |  | $ | 466,000 |  |  | $ | 466,000 |  |  | $ | 433,000 |  |  | $ | 430,000 |  |  | $ | — |
### Management Fee In July 2015, Aytu entered into an agreement with Ampio whereby Aytu agreed to pay Ampio $30,000 per month for shared overhead which includes costs related to the shared facility, corporate staff, and other miscellaneous overhead expenses. This agreement will be in effect until it is terminated in writing by both parties. ### ProstaScint Inventory Transfer Fee Aytu is obligated to pay $500,000 for the ProstaScint-related product inventory upon the inventory transfer in July 2015. ### Sponsored Research Agreement with Related Party Aytu entered into a Sponsored Research Agreement with Trauma Research LLC (“TRLLC”), a related party, in June 2013. Under the terms of the Sponsored Research Agreement, TRLLC agreed to work collaboratively in advancing the RedoxSYS System diagnostic platform through research and development efforts. The Sponsored Research Agreement may be terminated without cause by either party on 30 days’ notice. ### Clinical Research and Trial Obligations In connection with the Zertane clinical trials and RedoxSYS research studies, the remaining commitment is $329,000. ### Aytu Manufacturing and Commercial Development Aytu entered into agreements with manufacturing companies to build its RedoxSYS system. The current remaining commitment is $133,000. ### Office Lease In June 2015, Aytu entered into a 37 month operating lease. This lease has initial base rent of $2,900 a month, with total base rent over the term of the lease of approximately $112,000. The Company recognizes rental expense of the facility on a straight-line basis over the term of the lease. Differences between the straight-line net expenses on rent payments are classified as liabilities between current deferred rent and long-term deferred rent. Rent expense for the respective periods is as follows:
|  | Years Ended June 30,
|  | 2015 |  | 2014
Rent expense |  | $ | 51,000 |  |  | $ | 11,000 |

X
- References No definition available. + Details
Name: | us-gaap_CommitmentsAndContingenciesDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for commitments and contingencies. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 460 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=51674963&loc=d3e12565-110249 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 440 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308 + Details
Name: | us-gaap_CommitmentsAndContingenciesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration